Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Clears 79 First Generics In 2002 During Record-Breaking Year For ANDAs

Executive Summary

Generic versions of Glucophage (metformin), Accutane (isotretinoin) and Augmentin (amoxicillin/clavulanate) head a record-breaking year for first generic approvals by FDA

You may also be interested in...



Teva’s Generic Remeron Exclusivity Cut To Five Months By FDA Rules

Teva's generic Remeron (mirtazapine) will have only five months of marketing exclusivity from its approval date due to FDA's current interpretation of the trigger for first-to-file 180-day marketing exclusivity under the Waxman/Hatch Act, Teva reported in its Feb. 18 earnings teleconference

Teva’s Generic Remeron Exclusivity Cut To Five Months By FDA Rules

Teva's generic Remeron (mirtazapine) will have only five months of marketing exclusivity from its approval date due to FDA's current interpretation of the trigger for first-to-file 180-day marketing exclusivity under the Waxman/Hatch Act, Teva reported in its Feb. 18 earnings teleconference

Apotex Paxil Generics Earliest Launch Date Could Be September 2003

Apotex' earliest potential launch date for its generic version of GSK's Paxil is September 2003

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS041017

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel